Sanofi (SNY) Cash & Equivalents (2009 - 2026)

Sanofi has disclosed Cash & Equivalents across 18 years of filings, most recently posting $7.4 billion for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 57.55% year-over-year to $7.4 billion; the TTM figure through Jun 2026 stood at $7.4 billion (down 57.55% YoY), while the FY2025 annual figure was $8.9 billion, up 10.67% from the prior year.
• Cash & Equivalents came in at $7.4 billion for Q2 2026 at Sanofi, up from $6.9 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $17.4 billion in Q2 2025 to a low of $6.9 billion in Q1 2026.
• Average Cash & Equivalents over 5 years is $9.4 billion, with a median of $8.7 billion recorded in 2023.
• Year-over-year, Cash & Equivalents jumped 137.59% in 2025 and plunged 57.55% in 2026.
• Over 5 years, Cash & Equivalents stood at $13.0 billion in 2022, then retreated by 27.88% to $9.4 billion in 2023, then slipped by 15.15% to $8.0 billion in 2024, then grew by 12.09% to $8.9 billion in 2025, then slipped by 17.19% to $7.4 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $7.4 billion in Q2 2026, $6.9 billion in Q1 2026, and $8.9 billion in Q4 2025.